荟萃分析:酒精性肝硬化的戒酒率及其对预后的影响
该荟萃分析纳入19项队列研究共18833例酒精性肝硬化患者,旨在评估戒酒率、相关因素及戒酒对预后的影响。结果显示戒酒率为53.8%(CI: 44.6%-62.7%),戒酒与较低死亡风险(HR: 0.611, 95% CI: 0.506-0.738)和较低失代偿风险(HR: 0.612, 95% CI: 0.473-0.792)相关。
要点
- 酒精性肝硬化患者中戒酒率仅约53.8%,仍有一半患者持续饮酒。
- 戒酒与总生存率显著改善相关(HR 0.611),且在不同亚组中一致。
- 戒酒还显著降低肝失代偿风险(HR 0.612),支持将戒酒作为关键干预。
核心结论
- 戒酒与酒精性肝硬化患者总生存率显著改善相关,且仅约半数患者实现戒酒。
研究设计与样本
- 研究为系统综述与荟萃分析,检索Medline和Embase至2023年4月15日,纳入19项前瞻性或回顾性队列研究,共18833例已知酒精性肝硬化患者。
- 采用比例荟萃分析合并戒酒率,采用逆方差随机效应模型合并戒酒对比持续饮酒的风险比(HR)。
主要发现
- 戒酒率为53.8%(CI: 44.6%-62.7%)。
- 在平均随访48.6个月期间,持续饮酒者总生存率显著低于戒酒者(HR: 0.611, 95% CI: 0.506-0.738)。
- 戒酒与显著降低的肝失代偿风险相关(HR: 0.612, 95% CI: 0.473-0.792)。
- 上述结果在失代偿存在、研究设计及全程评估戒酒的敏感性/亚组分析中保持一致。
关键数值与推荐
- 戒酒率合并值为53.8%(95% CI: 44.6%-62.7%)。
- 戒酒对比持续饮酒的总生存HR为0.611(95% CI: 0.506-0.738),肝失代偿HR为0.612(95% CI: 0.473-0.792)。
临床怎么用
- 临床应积极筛查并促进酒精性肝硬化患者戒酒,因其与生存改善和失代偿风险降低相关。
- 戒酒率仅约一半,提示需加强戒酒干预策略以提高戒酒率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although alcohol abstinence may be an effective intervention for alcohol-associated cirrhosis, its association with prognosis has not been systematically assessed or quantified. AIMS: To determine the prevalence of alcohol abstinence, factors associated with alcohol abstinence and the impact of abstinence on morbidity and overall survival in people with alcohol-associated cirrhosis. METHODS: We searched Medline and Embase from inception to 15 April 2023 for prospective and retrospective cohort studies describing alcohol abstinence in people with known alcohol-associated cirrhosis. Meta-analysis of proportions for pooled estimates was performed. The method of inverse variance, employing a random-effects model, was used to pool the hazard ratio (HR) comparing outcomes of abstinent against non-abstinent individuals with alcohol-associated cirrhosis. RESULTS: We included 19 studies involving 18,833 people with alcohol-associated cirrhosis. The prevalence of alcohol abstinence was 53.8% (CI: 44.6%-62.7%). Over a mean follow-up duration of 48.6 months, individuals who continued to consume alcohol had significantly lower overall survival compared to those who were abstinent (HR: 0.611, 95% CI: 0.506-0.738). These findings remained consistent in sensitivity/subgroup analysis for the presence of decompensation, study design and studies that assessed abstinence throughout follow-up. Alcohol abstinence was associated with a significantly lower risk of hepatic decompensation (HR: 0.612, 95% CI: 0.473-0.792). CONCLUSIONS: Alcohol abstinence is associated with substantial improvement in overall survival in alcohol-associated cirrhosis. However, only half of the individuals with known alcohol-associated cirrhosis are abstinent.
引用
- Lim WH, Tay P, Ng CH, et al. Meta-analysis: Prevalence and impact of alcohol abstinence in alcohol-associated cirrhosis. Aliment Pharmacol Ther. 2024. PMID: 38303565. doi:10.1111/apt.17888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。